Skip to main content
SpringerLink
Log in

Pathological Classification and Biomarkers

  • Chapter
  • First Online:
Renal Cancer

  • 488 Accesses

Abstract

The classification of renal cell carcinoma (RCC) is mostly based on the cytological and architectural features of the tumour and the immunohistochemical expression profile. The current World Health Organisation (WHO) classification is composed of 14 sub-types of RCC. The number of entities recognised by the WHO has increased in recent years and continues to evolve as new or ‘emerging’ sub-types are considered for inclusion. In this chapter, we outline the key features of the different sub-types of RCC, including those associated with hereditary syndromes. We describe the characteristics of 2 ‘emerging’ entities that may be formally recognised in the future and briefly discuss the role of novel biomarkers in RCC.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
eBook
USD 16.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Kovacs G, Akhtar M, Beckwith BJ, Bugert P, Cooper CS, Delahunt B, et al. The Heidelberg classification of renal cell tumours. J Pathol. 1997 Oct;183(2):131–3.

    Article  CAS  PubMed  Google Scholar 

  2. Störkel S, Eble JN, Adlakha K, Amin M, Blute ML, Bostwick DG, et al. Classification of renal cell carcinoma: workgroup no. 1. Union Internationale Contre le cancer (UICC) and the American joint committee on cancer (AJCC). Cancer. 1997 Sep 1;80(5):987–9.

    Article  PubMed  Google Scholar 

  3. Williamson SR, Gill AJ, Argani P, Chen Y, Egevad L, Kristiansen G, et al. Report from the International Society of Urological Pathology (ISUP) consultation conference on molecular pathology of urogenital cancers: III: molecular pathology of kidney cancer. Am J Surg Pathol. 2020 Jul;44(7):e47–65.

    Article  PubMed  PubMed Central  Google Scholar 

  4. Moch H, Humphrey PA, Ulbright TM, Reuter VE, editors. WHO classification of tumours of the urinary system and male genital organs (4th edition). Lyon: IARC; 2016.

    Google Scholar 

  5. Moch H, Gasser T, Amin MB, Torhorst J, Sauter G, Mihatsch MJ. Prognostic utility of the recently recommended histologic classification and revised TNM staging system of renal cell carcinoma: a Swiss experience with 588 tumors. Cancer. 2000 Aug 1;89(3):604–14.

    Article  CAS  PubMed  Google Scholar 

  6. Amin MB, Amin MB, Tamboli P, Javidan J, Stricker H, Venturina M, et al. Prognostic impact of histologic subtyping of adult renal epithelial neoplasms: an experience of 405 cases. Am J Surg Pathol. 2002 Mar;26(3):281–91. https://doi.org/10.1097/00000478-200203000-00001.

    Article  PubMed  Google Scholar 

  7. Trpkov K, Hes O, Williamson SR, Adeniran AJ, Agaimy A, Alaghehbandan R, et al. New developments in existing WHO entities and evolving molecular concepts: the genitourinary pathology society (GUPS) update on renal neoplasia. Mod Pathol. 2021 Mar 4;34(7):1392–424.

    Article  PubMed  Google Scholar 

  8. Delahunt B, Cheville JC, Martignoni G, Humphrey PA, MagiGalluzzi C, McKenney J, et al. The International Society of Urological Pathology (ISUP) grading system for renal cell carcinoma and other prognostic parameters. Am J Surg Pathol. 2013;37:1490–504.

    Article  PubMed  Google Scholar 

  9. Thomas JO, Tawfik O. Recent advances in the diagnosis of renal cell carcinoma. Diagn Histopathol. 2008;14(4):157–63.

    Article  Google Scholar 

  10. Delahunt B. Advances and controversies in grading and staging of renal cell carcinoma. Mod Pathol. 2009 Jun;22(Suppl 2):S24–36.

    Article  PubMed  Google Scholar 

  11. Reuter VE, Argani P, Zhou M, Delahunt B. Members of the ISUP immunohistochemistry in diagnostic urologic pathology group. Best practices recommendations in the application of immunohistochemistry in the kidney tumors: report from the International Society of Urologic Pathology consensus conference. Am J Surg Pathol. 2014 Aug;38(8):e35–49.

    Article  PubMed  Google Scholar 

  12. Kim M, Joo JW, Lee SJ, Cho YA, Park CK, Cho NH. Comprehensive Immunoprofiles of renal cell carcinoma subtypes. Cancers (Basel). 2020 Mar 5;12(3):602.

    Article  CAS  PubMed  Google Scholar 

  13. Trpkov K, Hes O, Bonert M, Lopez JI, Bonsib SM, Nesi G, et al. Eosinophilic, solid, and cystic renal cell carcinoma: Clinicopathologic study of 16 unique, sporadic neoplasms occurring in women. Am J Surg Pathol. 2016 Jan;40(1):60–71.

    Article  PubMed  Google Scholar 

  14. Argani P, Reuter VE, Zhang L, Sung Y, Ning Y, Epstein JI, et al. TFEB-amplified renal cell carcinomas: an aggressive molecular subset demonstrating variable melanocytic marker expression and morphologic heterogeneity. Am J Surg Pathol. 2016 Nov;40(11):1484–95.

    Article  PubMed  PubMed Central  Google Scholar 

  15. Gupta S, Johnson SH, Vasmatzis G, Porath B, Rustin JG, Rao P, et al. TFEB-VEGFA (6p21.1) co-amplified renal cell carcinoma: a distinct entity with potential implications for clinical management. Mod Pathol. 2017 Jul;30(7):998–1012. https://doi.org/10.1038/modpathol.2017.24.

    Article  CAS  PubMed  Google Scholar 

  16. Argani P, Lae M, Hutchinson B, Reuter VE, Collins MH, Perentesis J, et al. Renal carcinomas with the t(6;11)(p21;q12): clinicopathologic features and demonstration of the specific alpha-TFEB gene fusion by immunohistochemistry, RT-PCR, and DNA PCR. Am J Surg Pathol. 2005;29:230–40.

    Article  PubMed  Google Scholar 

  17. Ohe C, Smith S, Sirohi D, Divatia M, De Peralta-Venturina M, Paner GP, et al. Reappraisal of morphological differences between renal medullary carcinoma, collecting duct carcinoma, and fumarate hydratase-deficient renal cell carcinoma. Am J Surg Pathol. 2018;42(3):279–92.

    Article  PubMed  PubMed Central  Google Scholar 

  18. Zao J, Eyzaguirre E. Clear cell papillary renal cell carcinoma. Arch Pathol Lab Med. 2019;143:1154–8.

    Article  Google Scholar 

  19. Nathany S, Monnapa V. Mucinous and spindle cell carcinoma: a review of histopathology and clinical and prognostic implications. Arch Pathol Lab Med. 2020;144(1):115–8.

    Article  CAS  PubMed  Google Scholar 

  20. Zhao M, He X, Teng X. Mucinous tubular and spindle cell renal cell carcinoma: a review of clinicopathologic aspects. Diagn Pathol. 2015;10:168.

    Article  PubMed  PubMed Central  Google Scholar 

  21. Amin MB, Maclennan GT, Gupta R, Grignon D, Paraf F, Viellefond A, et al. Tubulocystic carcinoma of the kidney: clinicopathologic analysis of 31 cases of a distinctive rare subtype of renal cell carcinoma. Am J Surg Pathol. 2009;33:384–92.

    Article  PubMed  Google Scholar 

  22. Tickoo SK, deParalta-Venturina MN, Harik LR, Worcester HD, Salama ME, Young AN, et al. Spectrum of epithelial neoplasms in end-stage renal disease: an experience from 66 tumor-bearing kidneys with emphasis on histologic patterns distinct from those in sporadic adult renal neoplasia. Am J Surg Pathol. 2006;30:141–53.

    Article  PubMed  Google Scholar 

  23. Enoki Y, Katoh G, Okabe H, Yanagisawa A. Clinicopathological features and CD57 expression in renal cell carcinoma in acquired cystic disease of the kidneys: with special emphasis on a relation to the duration of haemodialysis, the degree of calcium oxalate deposition, histological type, and possible tumorigenesis. Histopathology. 2010;56:384–94.

    Article  PubMed  Google Scholar 

  24. Lopez-Beltran A, Kirkali Z, Montironi R, Blancan A, Algaba F, Scarpelli M, et al. Unclassified renal cell carcinoma: a report of 56 cases. BJU Int. 2012;110:786–93.

    Article  PubMed  Google Scholar 

  25. Kiuru M, Launonen V, Hietala AK, Vierimaa O, Salovaara R, Arola J, Pukkala E, Sistonen P, Herva R, Aaltonen LA. Familial cutaneous leiomyomatosis is a two-hit condition associated with renal cell cancer of characteristic histopathology. Am J Pathol. 2001;159:825–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Launonen V, Vierimaa O, Kiuru M, Isola J, Roth S, Pukkala E, Sistonen P, Herva R, Aaltonen LA. Inherited susceptibility to uterine leiomyomas and renal cell cancer. Proc Natl Can Sci USA. 2001;13(98):3387–92.

    Article  Google Scholar 

  27. Gill AJ, Hes O, Papathomas T, Sedivcova M, Tan PH, Agaimy A, et al. Succinate dehydrogenase (SDH)-deficient renal cell carcinoma: a morphologically distinct entity: a clinicopathologic series of 36 tumors from 27 patients. Am J Surg Pathol. 2014;38:1588–602.

    Article  PubMed  PubMed Central  Google Scholar 

  28. Skala SL, Xiao H, Udager AM, Dhanasekaran SM, Shukla S, Zhang Y, et al. Detection of 6 TFEB-amplified renal cell carcinomas and 25 renal cell carcinomas with MITF translocations: systematic morphologic analysis of 85 cases evaluated by clinical TFE3 and TFEB FISH assays. Mod Pathol. 2018 Jan;31(1):179–97. https://doi.org/10.1038/modpathol.2017.99.

    Article  CAS  PubMed  Google Scholar 

  29. Gupta S, Argani P, Jungbluth AA, Chen Y, Tickoo SK, Fine SW, et al. TFEB expression profiling in renal cell carcinomas: Clinicopathologic correlations. Am J Surg Pathol. 2019 Nov;43(11):1445–61.

    Article  PubMed  PubMed Central  Google Scholar 

  30. Guo J, Tretiakova MS, Troxell ML, Osunkoya AO, Fadare O, Sangoi AR, et al. Tuberous sclerosis-associated renal cell carcinoma: a clinicopathologic study of 57 separate carcinomas in 18 patients multicenter study. Am J Surg Pathol. 2014 Nov;38(11):1457–67.

    Article  PubMed  Google Scholar 

  31. Li Y, Reuter VE, Matoso A, Netto GJ, Epstein JI, Argani P. Re-evaluation of 33 'unclassified' eosinophilic renal cell carcinomas in young patients. Histopathology. 2018 Mar;72(4):588–600. https://doi.org/10.1111/his.13395.

    Article  PubMed  Google Scholar 

  32. Palsgrove DN, Li Y, Pratilas CA, Lin M, Pallavajjalla A, Gocke C, et al. Eosinophilic solid and cystic (ESC) renal cell Carcinomas Harbor TSC mutations: molecular analysis supports an expanding Clinicopathologic Spectrum. Am J Surg Pathol. 2018 Sep;42(9):1166–81.

    Article  PubMed  PubMed Central  Google Scholar 

  33. Bihr S, Ohashi R, Moore AL, Rüschoff JH, Beisel C, Hermanns T, et al. Expression and mutation patterns of PBRM1, BAP1 and SETD2 Mirror specific evolutionary subtypes in clear cell renal cell carcinoma. Neoplasia. 2019 Feb;21(2):247–56.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  34. Ueda K, Suekane S, Kurose H, Chikui K, Nakiri M, Nishihara K, et al. Prognostic value of PD-1 and PD-L1 expression in patients with metastatic clear cell renal cell carcinoma. Urol Oncol. 2018 Nov;36(11):499.e9–499.e16. https://doi.org/10.1016/j.urolonc.2018.07.003.

    Article  CAS  PubMed  Google Scholar 

  35. Buonerba C, Dolce P, Iaccarino S, Scafuri L, Verde A, Costabile F, et al. Outcomes associated with first-line anti-PD-1/PD-L1 agents vs. Sunitinib in patients with Sarcomatoid renal cell carcinoma. A Systematic Review and Meta-Analysis Cancers (Basel). 2020 Feb 10;12(2):408.

    Article  CAS  PubMed  Google Scholar 

  36. Sommer U, Eckstein M, Ammann J, Braunschweig T, Macher-Göppinger S, Schwamborn K, et al. Multicentric analytical and inter-observer comparability of four clinically developed programmed death-ligand 1 immunohistochemistry assays in advanced clear-cell renal cell carcinoma. Clin Genitourin Cancer. 2020 Oct;18(5):e629–42.

    Article  PubMed  Google Scholar 

  37. Kim KS, Sekar RR, Patil D, Dimarco MA, Kissick HT, Bilen MA, et al. Evaluation of programmed cell death protein 1 (PD-1) expression as a prognostic biomarker in patients with clear cell renal cell carcinoma. Onco Targets Ther. 2018 Jan 10;7(4):e1413519.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. St Georges University NHS Foundation Trust, London, UK

    Nicholas Archard, Athanasia Vargiamidou, Caitlin Beggan & Colan M. Ho-Yen

Authors
  1. Nicholas Archard
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Athanasia Vargiamidou
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Caitlin Beggan
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Colan M. Ho-Yen
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Colan M. Ho-Yen .

Editor information

Editors and Affiliations

  1. Department Urology, St Georges University Hospital NHS Foundation Trust, London, UK

    Christopher Anderson

  2. Department Uro-Oncology, St Georges University Hospital NHS Foundation Trust, London, UK

    Mehran Afshar

Rights and permissions

Reprints and permissions

Copyright information

© 2022 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Archard, N., Vargiamidou, A., Beggan, C., Ho-Yen, C.M. (2022). Pathological Classification and Biomarkers. In: Anderson, C., Afshar, M. (eds) Renal Cancer . Springer, Cham. https://doi.org/10.1007/978-3-030-84756-2_5

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-84756-2_5

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-84755-5

  • Online ISBN: 978-3-030-84756-2

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation